Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor.
Aggressive thoracic tumor
Immune checkpoint inhibitor
SMARCA4
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
02
11
2020
accepted:
19
01
2021
entrez:
31
3
2021
pubmed:
1
4
2021
medline:
1
4
2021
Statut:
epublish
Résumé
SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.
Identifiants
pubmed: 33786285
doi: 10.1007/s13691-021-00472-4
pii: 472
pmc: PMC7947161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
112-115Informations de copyright
© The Japan Society of Clinical Oncology 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
J Thorac Oncol. 2020 Feb;15(2):231-247
pubmed: 31751681
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Thorac Oncol. 2020 Aug;15(8):e133-e136
pubmed: 32718537
Nat Genet. 2015 Oct;47(10):1200-5
pubmed: 26343384
Am J Hum Genet. 2010 Feb 12;86(2):279-84
pubmed: 20137775
Nat Rev Cancer. 2011 Jun 09;11(7):481-92
pubmed: 21654818
Ann Oncol. 2019 Aug 1;30(8):1401-1403
pubmed: 31114851
J Thorac Oncol. 2020 May;15(5):766-776
pubmed: 31988001
Immunotherapy. 2020 Jun;12(8):563-569
pubmed: 32363992
Nat Genet. 2014 May;46(5):438-43
pubmed: 24658002